GLOW Blend 70mg (with Bacteriostatic Water)

The Glow Blend is a three-peptide research formulation that combines the copper-binding tripeptide GHK-Cu, the pentadecapeptide BPC-157, and the thymosin β4 fragment TB-500 into a single lyophilized vial. The typical formulation supplies 50 mg of GHK-Cu, 10 mg of BPC-157, and 10 mg of TB-500 for a total of 70 mg of peptide content. The blend exists as a research-peptide product because each of its three components has an independent literature in the broader conversation around tissue remodeling, collagen biology, and cellular repair, and the combined product provides a research-convenience format for studying all three together.

The "Glow" in the product name reflects the cosmetic and skin-biology research conversation that has surrounded GHK-Cu for decades — the copper-binding tripeptide has the most established literature among the three in the skin-research context, and the broader blend has therefore been associated with research conversations that intersect dermal, connective-tissue, and broader tissue-remodeling endpoints. The name is informal product nomenclature rather than a formal scientific designation; the scientific literature refers to the components by their individual names (GHK-Cu, BPC-157, TB-500) and to combination work as combination studies of these specific compounds.

This page is an educational reference for readers who want to understand what each component of the Glow Blend actually is, where each came from, what the published literature describes about each, and what conceptual rationale underlies pairing them together in a single research blend. It is not a medical guide, does not describe any therapy or personal-use protocol, and makes no claims about cosmetic, dermatological, or other effects in people. The Glow Blend supplied as a research peptide is intended for laboratory and analytical work only, and the entire discussion below stays within that context.

The Glow Blend contains three structurally and mechanistically distinct synthetic peptides co-lyophilized in a single research vial.

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). The peptide portion is one of the smallest functional peptides characterized in the cell-biology literature, with a molecular mass of approximately 340 daltons for the apo-peptide; the copper(II) complex adds the bound metal ion. GHK was originally isolated by Loren Pickart from human plasma in the 1970s and has been studied for decades for its effects on collagen gene expression, on a wide range of skin-biology endpoints, and on broader tissue-remodeling pathways. The copper coordination is integral to most of the proposed mechanisms — the copper ion participates in the redox chemistry and in the broader signaling effects attributed to the complex in the cell-biology literature.

BPC-157 is a synthetic fifteen-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular mass ~1,419 daltons) derived from a protective protein originally identified in human gastric juice. The peptide was characterized by Sikiric and colleagues in Zagreb starting in the early 1990s and has an extensive animal-model literature on connective-tissue, vascular, and gastric-protection endpoints. It is proline-rich and relatively protease-resistant for a peptide of its size.

TB-500 is a short synthetic peptide containing the active LKKTETQ motif of the actin-binding protein thymosin β4. Full-length thymosin β4 was originally isolated from calf thymus by Allan Goldstein and colleagues in the 1960s and has been characterized as a major intracellular actin-sequestering protein with effects on cytoskeletal dynamics and cell migration. TB-500 reproduces the short active sequence in a synthetic, research-tractable form.

The three components are structurally unrelated and do not share a common scaffold or proximal molecular receptor. Their pairing in the Glow Blend reflects the research-community argument that the three compounds cover three different but conceptually complementary aspects of the broader tissue-remodeling conversation: GHK-Cu in copper-binding and collagen-gene-expression pathways, BPC-157 in vascular and growth-factor-receptor pathways, and TB-500 in cytoskeletal and migration pathways.

Each component of the Glow Blend has its own history.

GHK was first identified by Loren Pickart in the early 1970s. Pickart's work began with the observation that liver explants from older animals could be rejuvenated functionally when cultured with serum from younger animals, and the search for the active factor led to isolation of the GHK tripeptide. Pickart's subsequent work, sustained over decades, characterized the copper(II) complex GHK-Cu and its effects on collagen biology, skin-biology endpoints, and broader tissue-remodeling pathways. Through the 1980s, 1990s, and 2000s, the GHK-Cu literature expanded substantially across cell-biology, dermatology, and broader connective-tissue research contexts. The cosmetic-formulation side of the GHK-Cu story took off in parallel, with the peptide becoming one of the most recognized cosmetic-active research peptides in the dermatology and skincare-research conversations.

BPC-157's history begins in the early 1990s in Croatia, where Predrag Sikiric and colleagues at the University of Zagreb isolated and characterized the active fragment from human gastric juice. The Sikiric group published a sustained body of literature characterizing BPC-157 across many animal-model contexts, with the work continuing through the 2000s and 2010s.

TB-500's history derives from the 1960s isolation of thymosin β4 from calf thymus by Allan Goldstein at the Albert Einstein College of Medicine. The cell-biology characterization of thymosin β4 as an actin-binding protein developed through the 1970s and 1980s; the synthetic short-peptide form (TB-500) emerged later as a research-tractable surrogate.

The combined Glow Blend is more recent product nomenclature. As the research-peptide market expanded in the 2010s, multiple suppliers began offering three-component blends that paired GHK-Cu with the BPC-157 + TB-500 "Wolverine Stack" combination. The name "Glow Blend" reflects the dermatology and cosmetic-research framing that GHK-Cu brings to the combination. The blend is not a formally named scientific entity but a research-convenience product whose three components each have their own substantial individual literature.

The science of the Glow Blend is the science of three independent compounds whose proposed mechanisms in the published literature have meaningful conceptual overlap in the broader tissue-remodeling conversation.

• Three-component lyophilized research blend: GHK-Cu (50 mg) + BPC-157 (10 mg) + TB-500 (10 mg).
• GHK-Cu is the copper(II) complex of the tripeptide Gly-His-Lys, characterized for decades in collagen-gene-expression and skin-biology research.
• BPC-157 is a fifteen-amino-acid synthetic peptide derived from a gastric protective protein, with extensive Sikiric-group animal-model literature.
• TB-500 is a short synthetic peptide reproducing the active LKKTETQ motif of the actin-binding protein thymosin β4.
• The three components are structurally unrelated; the blend provides research convenience for studying complementary tissue-remodeling pathways together.

Each of the three Glow Blend components has its own structural identity.

GHK-Cu's peptide portion is the tripeptide Gly-L-His-L-Lys (molecular mass ~340 daltons for the apo-peptide). The histidine and lysine side chains, together with the N-terminal amine and the histidine imidazole, provide the coordination sites that bind copper(II) in a square-planar geometry typical of copper-tripeptide complexes. The bound copper increases the total mass and is integral to the chemistry of the complex.

BPC-157 has the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular mass of approximately 1,419 daltons in its free-acid form. The sequence is notably proline-rich, which contributes to its conformational rigidity and relative protease resistance.

TB-500 in its common research form is a short synthetic peptide containing the LKKTETQ active motif, typically as part of an extended ~17-residue sequence with a molecular mass near 1,700 daltons. The exact extended sequence varies somewhat across suppliers.

In a typical Glow Blend vial, the three components are co-lyophilized in defined mass amounts (50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 = 70 mg total) supplied as a single dry mixture for reconstitution in sterile bacteriostatic water for research use. The three peptides do not interact covalently and remain distinct molecular entities in solution after reconstitution.

The Glow Blend is studied in laboratory contexts that intersect the independent research literatures of its three components.

In skin-biology and dermal-research contexts, GHK-Cu provides the most prominent research footprint of the three components, with an extensive published literature on effects on collagen synthesis, fibroblast biology, skin-barrier function, and broader dermatological endpoints. The combined blend is used in laboratory work that aims to evaluate skin-related endpoints in a multi-pathway framework, with BPC-157 and TB-500 adding complementary tissue-repair perspectives.

In connective-tissue research — including tendon, ligament, and broader musculoskeletal-repair contexts — BPC-157 and TB-500 each have established individual literatures, and GHK-Cu adds the collagen-and-extracellular-matrix dimension through its well-characterized effects on collagen-related gene expression. The blend has been used in laboratory work characterizing connective-tissue endpoints across these complementary mechanisms.

In wound-healing and tissue-repair models, all three components have independent connections to wound-healing endpoints in the published literature. GHK-Cu's wound-healing work is anchored in its established skin-biology literature; BPC-157's wound-healing work extends from its gastric-protection and broader tissue-repair animal-model work; TB-500's wound-healing work derives from the broader thymosin β4 cell-migration and tissue-repair literature.

In angiogenesis research, both BPC-157 and TB-500 have independent published connections to angiogenesis endpoints, and GHK-Cu has some related connections through its broader tissue-remodeling research. The Glow Blend has been used in laboratory work characterizing angiogenesis endpoints across the multiple proposed mechanisms.

In broader cell-biology research on tissue remodeling and extracellular-matrix dynamics, the three components have been studied together for their combined contribution to research conversations involving collagen, vascular response, cell migration, and the broader pathway-network underlying tissue remodeling.

Across all of these contexts, the research applications are laboratory and analytical in nature. The Glow Blend supplied as a research peptide is not used in any approved-medicine clinical context, and the research applications listed above are framed as laboratory-investigation use of a research-peptide blend.

The Glow Blend's three components each have distinct comparators, and the blend itself sits within a broader landscape of multi-peptide research-blend products.

The Glow Blend is a three-peptide research formulation combining GHK-Cu (50 mg), BPC-157 (10 mg), and TB-500 (10 mg) in a single co-lyophilized vial. The three components are structurally and mechanistically unrelated and each has its own substantial individual research literature. The pairing reflects a research-community argument that the three compounds cover complementary aspects of the broader tissue-remodeling conversation: GHK-Cu in copper-binding and collagen-gene-expression pathways, BPC-157 in vascular and growth-factor pathways, and TB-500 in cytoskeletal and migration pathways.

GHK-Cu has the most established and most diverse literature among the three, anchored in Loren Pickart's foundational 1970s work and extended across decades of cell-biology and dermatology research. BPC-157 is anchored in the multi-decade Sikiric-group animal-model literature and is particularly associated with connective-tissue, vascular, and gastric-protection endpoints. TB-500 derives from the long-running cell-biology literature on thymosin β4 and centers on actin and cell-migration mechanisms.

The "Glow" framing reflects the skin-biology context that GHK-Cu brings, but the broader blend has applications across multiple tissue-remodeling research conversations beyond skin biology. Dedicated head-to-head comparisons of the combined blend versus the individual components are limited in the published literature, and the rationale for combining all three is more community-driven than rigorously evaluated.

None of the three components is approved as a medicine in major international regulatory jurisdictions. The Glow Blend supplied as a research peptide is intended for laboratory and analytical work only, and educational discussion should remain within that framing rather than drift into therapeutic or cosmetic claims about humans or animals.

For students, researchers, and curious readers approaching the Glow Blend for the first time, the most accurate framing is of three distinct synthetic compounds — one anchored in copper-binding and collagen biology, one in gastric-protection-derived tissue-repair research, one in actin and cell-migration research — packaged together as a research-peptide convenience blend with substantial individual research literatures and a conceptually coherent though community-driven rationale for combination.